This post was originally published on this site Two compounds found in coffee might be able to slow the growth and migration of prostate cancers, a pilot study conducted in drug-resistant cancer cells and a mouse model report. As such, two possible therapeutic candidates for drug-resistant prostate cancers may have been identified in this work,…
This post was originally published on this site Patients with advanced sarcoidosis have limited daily life physical activity, mostly because their lungs’ maximal oxygen uptake is reduced, a study shows. The findings of the study, “Daily life physical activity in patients with chronic stage IV sarcoidosis: A multicenter cohort study,” were published in the journal Health…
This post was originally published on this site TG Therapeutics‘ umbralisib (TGR-1202), an inhibitor of the PI3K delta protein, has shown promising efficacy and safety in patients with relapsed or refractory marginal zone lymphoma, reducing cancer volume in more than half of patients in a Phase 2b trial. Findings from the ongoing trial — called UNITY-NHL (NCT02793583) — were presented at the American…
This post was originally published on this site Treatment with the radioactive molecule lutetium-177-PSMA-617 (LuPSMA), which binds to the prostate-specific membrane antigen, is a potential therapeutic strategy for patients with metastatic castration-resistant prostate cancer (CRPC), results from a pilot study suggest. The findings were shared in the poster, “Results of a 50 patient single-centre phase…
This post was originally published on this site Treatment with DPX-Survivac plus intermittent low-dose cyclophosphamide continues to show promise in women with advanced recurrent ovarian cancer, the second part of a Phase 1/2 trial shows. Interim data from the first six patients revealed that five patients (83%) achieved stable disease, including two tumor regressions —…
This post was originally published on this site The European Medicines Agency‘s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Celgene‘s Revlimid (lenalidomide) and Pomalyst (pomalidomide, marketed as Imnovid in Europe) as combination therapies with Velcade (bortezomib) and dexamethasone for adult patients with multiple myeloma. In the case of Revlimid, the triple…
This post was originally published on this site A Phase 1 study has started dosing patients who have newly diagnosed high-grade gliomas with a combination of Candel Therapeutics‘ gene-mediated cytotoxic immunotherapy (GMCI) plus Opdivo (nivolumab) and standard of care therapy. GMCI (aglatimagene besadenovec plus prodrug) is an “off-the-shelf” adenovirus-based medicine meant to increase the amount…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has proposed a set of new policies to modernize and improve the quality of mammography screenings for breast cancer. The federal agency is confident that such measures may help women facing the disease make informed decisions about their health care.…
This post was originally published on this site The Leukemia & Lymphoma Society’s (LLS) Silicon Valley Student of the Year drive netted more than $297,000 to support the organization’s research and patient support efforts. Funds were raised through the LLS’ Silicon Valley & Monterey Bay Area chapter by some 39 high school students. The top fundraisers were Evergreen…
This post was originally published on this site Therapy candidate INB03, meant to inactivate a kind immunosuppressive cell called myeloid-derived suppressor cells (MDSCs) while boosting anti-tumor immune cells, may help overcome resistance to immunotherapies, including immune checkpoint inhibitors, INmune Bio’s co-founder Raymond J. Tesi, MD, said at a conference. Tesi, CEO of INmune Bio, presented the potentialities…
